Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase.
JingCheng ZhangSheng ZhouSiSi JiangFang HeYan TuHuiXian Hu
Published in: Journal of cancer research and clinical oncology (2024)
These findings reveal that imatinib mesylate effectively reduces the carcinogenic function of c-MYC in DHL, providing novel strategies for developing therapies targeting c-MYC-driven DHL.